We live in an era of industrial transformation with the implementation of digital tools to handle increasing data amounts, as well as automation to facilitate workflows. Of course, this development does not stop at the bioprocess industry. Digital tools offer the possibility to enhance working efficiency and monitor your bioreactor culture without the need to be in the lab. Introducing BioNsight® cloud, a true cloud-based software solution for bioprocess monitoring and analysis, fully integrated into the Eppendorf bioprocess control software DASware® control 6.

Matt Gunnison was appointed as the new CEO of Biosynth, headquartered in Staad (CH). He started in November.

Researcher from China, Germany and the US have developed a method for designing large new proteins with pre-defined properties in the lab using Alphafold2.

Circio Holding ASA has inked a collaboration with Certest Biotec, SL to find  and test circVec LNP-formulations to deliver its circular RNA therapeutics to target tissues for gene therapies.

A dispute is brewing in Europe over climate-friendly protein production in fermenters between EU member states that are in favour of or against protein production independent of agricultural land. Germany, Denmark and supporters called on the EU Commission to formulate a European protein strategy triggering protests from farmers.

The Society for Laboratory Automation and Screening (SLAS) is transforming the global life sciences community by uniting interdisciplinary researchers and technology providers to drive innovation in laboratory automation and research.

The Young European Biotech Network (YEBN) is preparing for a busy semester, with a variety of events and initiatives planned through the end of 2024. From launching a new community platform to hosting key events, YEBN aims to support innovation, facilitate collaboration, and address the evolving needs of the biotech community.

Belgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development.

Innate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL).

The French biotech company DiogenX is further strengthening its management team. In November, Dr Klara Owen was appointed as Chief Medical Officer.